{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:29:31Z","timestamp":1786998571235,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35-GM131839"],"award-info":[{"award-number":["R35-GM131839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD20012"],"award-info":[{"award-number":["S10OD20012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA290778"],"award-info":[{"award-number":["R01-CA290778"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01-OD034451"],"award-info":[{"award-number":["K01-OD034451"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1-TR001453"],"award-info":[{"award-number":["UL1-TR001453"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K01-OD034451"],"award-info":[{"award-number":["K01-OD034451"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R35-GM131839"],"award-info":[{"award-number":["R35-GM131839"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA290778"],"award-info":[{"award-number":["R01-CA290778"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD20012"],"award-info":[{"award-number":["S10OD20012"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ymthe.2026.01.033","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:41:53Z","timestamp":1769701313000},"page":"2963-2982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth"],"prefix":"10.1016","volume":"34","author":[{"given":"Claire E.","family":"Tocheny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianna E.","family":"Buchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Dahlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan H.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi A.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel O.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael-Anthony","family":"Card","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur M.","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-2980","authenticated-orcid":false,"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.01.033_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/1478-811X-7-14","article-title":"Expression and function of the insulin receptor substrate proteins in cancer","volume":"7","author":"Mardilovich","year":"2009","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ymthe.2026.01.033_bib2","article-title":"The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target","volume":"12","author":"Lee","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ymthe.2026.01.033_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.canlet.2013.03.030","article-title":"IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors","volume":"338","author":"Porter","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2026.01.033_bib4","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97398","article-title":"IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma","volume":"3","author":"Zhu","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.01.033_bib5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10549-011-1353-1","article-title":"Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer","volume":"130","author":"Clark","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2026.01.033_bib6","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1128\/MCB.24.22.9726-9735.2004","article-title":"Involvement of insulin receptor substrate 2 in mammary tumor metastasis","volume":"24","author":"Nagle","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib7","doi-asserted-by":"crossref","first-page":"8894","DOI":"10.1158\/0008-5472.CAN-09-1152","article-title":"Hypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion","volume":"69","author":"Mardilovich","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00590-17","article-title":"Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2","volume":"38","author":"Mercado-Matos","year":"2018","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib9","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.1038\/sj.onc.1204920","article-title":"Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines","volume":"20","author":"Jackson","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2026.01.033_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111759","article-title":"The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2\/PI3K-mediated regulation of MYC","volume":"41","author":"Lee","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.01.033_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-021-06221-8","article-title":"Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)","volume":"188","author":"Haddad","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2026.01.033_bib12","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/0008-5472.CAN-09-2141","article-title":"Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes","volume":"70","author":"Novosyadlyy","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10549-017-4375-5","article-title":"A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer","volume":"165","author":"Rugo","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2026.01.033_bib15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/acsptsci.2c00110","article-title":"Nedosiran, a Candidate siRNA Drug for the Treatment of Primary Hyperoxaluria: Design, Development, and Clinical Studies","volume":"5","author":"Liu","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ymthe.2026.01.033_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.033_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.033_bib18","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.033_bib19","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.033_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.033_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.033_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.01.033_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.033_bib25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.ymthe.2024.03.035","article-title":"RNAi mediated silencing of STAT3\/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors","volume":"32","author":"Ganesh","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.033_bib26","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/s41467-024-45609-0","article-title":"Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy","volume":"15","author":"Hoogenboezem","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.033_bib27","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo","volume":"47","author":"Biscans","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102080","article-title":"Dendritic amphiphilic siRNA: Selective albumin binding, in vivo efficacy, and low toxicity","volume":"34","author":"Fakih","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.01.033_bib29","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1093\/nar\/gkae260","article-title":"Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo","volume":"52","author":"Sarli","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib30","doi-asserted-by":"crossref","first-page":"E6490","DOI":"10.1073\/pnas.1621240114","article-title":"Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing","volume":"114","author":"Sarett","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.01.033_bib31","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69\u2013GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib32","article-title":"Albumin-binding dendritic siRNA improves delivery and efficacy to solid tumors in a melanoma model","volume":"36","author":"Fakih","year":"2025","journal-title":"Mol. Ther. Nucleic Acid"},{"key":"10.1016\/j.ymthe.2026.01.033_bib33","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1021\/jacs.7b02917","article-title":"Development of DNA Nanostructures for High-Affinity Binding to Human Serum Albumin","volume":"139","author":"Lacroix","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2026.01.033_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.38","article-title":"Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain","volume":"4","author":"Alterman","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.01.033_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1165\/rcmb.2015-0012OC","article-title":"Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages","volume":"53","author":"Tarique","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib36","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1093\/nar\/gky745","article-title":"Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs","volume":"46","author":"Shmushkovich","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib37","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41587-024-02336-7","article-title":"Enhancing siRNA efficacy in vivo with extended nucleic acid backbones","volume":"43","author":"Yamada","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib38","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.ymthe.2020.12.023","article-title":"Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles","volume":"29","author":"Biscans","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.033_bib39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/36116","article-title":"Disruption of IRS-2 causes type 2 diabetes in mice","volume":"391","author":"Withers","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.01.033_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102117","article-title":"Multispecies-targeting siRNAs for the modulation of JAK1 in the skin","volume":"35","author":"Tang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.01.033_bib41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2337\/db14-0432","article-title":"Insulin receptor substrate-2 (Irs2) in endothelial cells plays a crucial role in insulin secretion","volume":"64","author":"Hashimoto","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.ymthe.2026.01.033_bib42","doi-asserted-by":"crossref","first-page":"14536","DOI":"10.1074\/jbc.M410227200","article-title":"Insulin Receptor Substrate 2 Plays Diverse Cell-specific Roles in the Regulation of Glucose Transport","volume":"280","author":"Sadagurski","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.01.033_bib43","doi-asserted-by":"crossref","first-page":"ra17","DOI":"10.1126\/scisignal.1164795","article-title":"Type I IL-4Rs Selectively Activate IRS-2 to Induce Target Gene Expression in Macrophages","volume":"1","author":"Heller","year":"2008","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymthe.2026.01.033_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104119","article-title":"The roles of tumor-associated macrophages in tumor angiogenesis and metastasis","volume":"353","author":"Fu","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ccr.2008.01.034","article-title":"HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion","volume":"13","author":"Du","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.01.033_bib46","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1084\/jem.20072602","article-title":"Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages","volume":"205","author":"Sierra","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.01.033_bib47","doi-asserted-by":"crossref","first-page":"11230","DOI":"10.1074\/jbc.M113.544999","article-title":"Insulin receptor substrate 1\/2 (IRS1\/2) regulates Wnt\/beta-catenin signaling through blocking autophagic degradation of dishevelled2","volume":"289","author":"Geng","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.01.033_bib48","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/j.devcel.2021.11.006","article-title":"Distinct contributions of partial and full EMT to breast cancer malignancy","volume":"56","author":"L\u00fc\u00f6nd","year":"2021","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ymthe.2026.01.033_bib49","doi-asserted-by":"crossref","first-page":"13073","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.01.033_bib50","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.01.033_bib52","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/0008-5472.CAN-14-2211","article-title":"Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein","volume":"75","author":"Kamphorst","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib53","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.7150\/thno.34883","article-title":"Secreted protein acidic and rich in cysteine mediates active targeting of human serum albumin in U87MG xenograft mouse models","volume":"9","author":"Park","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2026.01.033_bib54","doi-asserted-by":"crossref","first-page":"48416","DOI":"10.1016\/j.ijpharm.2015.02.037","article-title":"The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer","volume":"484","author":"Wan","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2026.01.033_bib55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/1541-7786.MCR-16-0243-T","article-title":"Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC","volume":"15","author":"Guttlein","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib56","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41565-021-00897-1","article-title":"Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer","volume":"16","author":"Li","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12977","article-title":"Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity","volume":"7","author":"Kubota","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.033_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI25735","article-title":"Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth","volume":"116","author":"Dong","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.01.033_bib59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature14971","article-title":"A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity","volume":"525","author":"Waclaw","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.01.033_bib60","first-page":"261","article-title":"Mouse 4T1 breast tumor model","volume":"525","author":"Pulaski","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib61","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1128\/MCB.21.15.5082-5093.2001","article-title":"Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion","volume":"21","author":"Shaw","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib62","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1074\/jbc.M808282200","article-title":"Growth hormone inhibition of glucose uptake in adipocytes occurs without affecting GLUT4 translocation through an insulin receptor substrate-2-phosphatidylinositol 3-kinase-dependent pathway","volume":"284","author":"Sasaki-Suzuki","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.01.033_bib63","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41598-021-83603-4","article-title":"MYD88 signals induce tumour-initiating cell generation through the NF-kappaB-HIF-1alpha activation cascade","volume":"11","author":"Tanimura","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.01.033_bib64","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3183","article-title":"Crk adaptor proteins act as key signaling integrators for breast tumorigenesis","volume":"14","author":"Fathers","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib65","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr1631","article-title":"p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy","volume":"8","author":"Frackelton","year":"2006","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.033_bib66","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41467-024-46283-y","article-title":"GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer","volume":"15","author":"Ye","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.033_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220567","article-title":"Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC)","volume":"14","author":"Piper","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.01.033_bib68","first-page":"5505","article-title":"Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma","volume":"16","author":"You","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ymthe.2026.01.033_bib69","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mc.21935","article-title":"Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer","volume":"52","author":"Wang","year":"2013","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ymthe.2026.01.033_bib70","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13000-017-0633-4","article-title":"Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma","volume":"12","author":"Wang","year":"2017","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib71","doi-asserted-by":"crossref","first-page":"18603","DOI":"10.1074\/jbc.M114.564070","article-title":"Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3beta to regulate aerobic glycolysis","volume":"289","author":"Landis","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.01.033_bib72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2020.04.020","article-title":"Detailed cellular assessment of albumin-binding oligonucleotides: Increased stability and lower non-specific cell uptake","volume":"324","author":"Lacroix","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ymthe.2026.01.033_bib73","doi-asserted-by":"crossref","first-page":"24148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.01.033_bib74","first-page":"465","article-title":"Ultrasonography as the Gold Standard for In Vivo Volumetric Determination of Chemically-induced Mammary Tumors","volume":"30","author":"Faustino-Rocha","year":"2016","journal-title":"In vivo"},{"key":"10.1016\/j.ymthe.2026.01.033_bib75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/nat.2019.0840","article-title":"RT-qPCR Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNAi Therapeutics","volume":"30","author":"Castellanos-Rizaldos","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2026.01.033_bib76","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1758-907X-1-16","article-title":"In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR)","volume":"1","author":"Landesman","year":"2010","journal-title":"Silence"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:32:39Z","timestamp":1781829159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525001626000341"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.01.033","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.07.29.667434","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}